Drug Trial Radar · NCT07709000
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 14, 2026
Primary completion
Nov 16, 2033
Study completion Nov 16, 2033
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.
Conditions
- Chronic Lymphocytic Leukaemia
- Small Lymphocytic Lymphoma
- Hematologic Malignancies
Interventions
MK-1045Biological
Intravenous (IV) infusion
Acetaminophen (or similar antipyretic)Drug
Oral administration as a premedication
Diphenhydramine (or similar antihistamine)Drug
Per approved product label as a premedication
DexamethasoneDrug
IV administration as a premedication
TocilizumabBiological
IV administration as a rescue medication
Tocilizumab biosimilarBiological
IV administration as a rescue medication
SiltuximabBiological
IV administration as a rescue medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A Part 1: Number of Participants Who Experience Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 29 days
- Cohort A Part 1: Number of Participants Who Experience an AETime frame: Up to approximately 27 months
- Cohort A Part 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 24 months
- Cohort A Parts 1 and 2: Objective Response Rate (ORR)Time frame: Up to approximately 66 months
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Hospital Pablo Tobon Uribe ( Site 0601)
Medellín, Antioquia, Colombia · Recruiting
Los Cobos Medical Center ( Site 0607)
Bogotá, Bogota D.C., Colombia · Recruiting
Rambam Health Care Campus ( Site 0803)
Haifa, Israel · Recruiting
Shaare Zedek Medical Center ( Site 0801)
Jerusalem, Israel · Recruiting
Haddasah Medical Center ( Site 0800)
Jerusalem, Israel · Recruiting
Sheba Medical Center ( Site 0802)
Ramat Gan, Israel · Recruiting
Sourasky Medical Center ( Site 0804)
Tel Aviv, Israel · Recruiting
Hospital General Universitario Gregorio Marañón ( Site 1103)
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre ( Site 1104)
Madrid, Spain · Recruiting
Hospital Clinico Universitario de Salamanca ( Site 1102)
Salamanca, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.